Cara Therapeutics, Inc. (CARA)
15.96
-0.69 (-4.14%)
Inactive · Last trade price on Apr 15, 2025
Cara Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 37.9 | 51.78 | 63.74 | 13.45 | 31.68 |
Short-Term Investments | - | 48.98 | 81.66 | 153.58 | 149.24 |
Cash & Short-Term Investments | 37.9 | 100.76 | 145.4 | 167.04 | 180.93 |
Cash Growth | -62.38% | -30.70% | -12.95% | -7.68% | 16.72% |
Accounts Receivable | 0.41 | 2.77 | 3.26 | - | - |
Other Receivables | 4.09 | 1.25 | 1.19 | 1.15 | 2.06 |
Receivables | 4.5 | 4.02 | 4.45 | 1.15 | 2.06 |
Inventory | 0.9 | 2.82 | 2.38 | 2.58 | - |
Prepaid Expenses | 0.53 | 8.15 | 16.27 | 2.52 | 12.08 |
Restricted Cash | - | 0.41 | 0.41 | - | - |
Total Current Assets | 43.83 | 116.16 | 168.91 | 173.29 | 195.07 |
Property, Plant & Equipment | - | 8.19 | 1.98 | 3.6 | 5.12 |
Long-Term Investments | - | - | 11.35 | 69.75 | 70.57 |
Other Long-Term Assets | - | 1.5 | - | 0.41 | 0.41 |
Total Assets | 43.83 | 125.84 | 182.24 | 247.06 | 271.16 |
Liabilities
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 1.43 | 11.58 | 9.6 | 5.63 | 4.89 |
Accrued Expenses | 2.54 | 14.01 | 11.94 | 10.24 | 11.99 |
Current Portion of Leases | - | - | 1.92 | 1.76 | 1.6 |
Total Current Liabilities | 3.97 | 25.59 | 23.46 | 17.62 | 18.48 |
Long-Term Debt | 44.45 | 37.08 | - | - | - |
Long-Term Leases | - | 6.09 | - | 1.92 | 3.67 |
Total Liabilities | 48.42 | 68.76 | 23.46 | 19.53 | 22.16 |
Shareholders' Equity
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0.01 | 0.01 | 0.05 | 0.05 | 0.05 |
Additional Paid-In Capital | 751.01 | 742.09 | 726.63 | 708.59 | 641.2 |
Retained Earnings | -755.61 | -684.75 | -566.23 | -480.76 | -392.32 |
Comprehensive Income & Other | - | -0.26 | -1.67 | -0.36 | 0.07 |
Shareholders' Equity | -4.59 | 57.09 | 158.78 | 227.52 | 249 |
Total Liabilities & Equity | 43.83 | 125.84 | 182.24 | 247.06 | 271.16 |
Additional Metrics
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 44.45 | 43.17 | 1.92 | 3.67 | 5.28 |
Net Cash (Debt) | -6.55 | 57.59 | 154.83 | 233.12 | 246.22 |
Net Cash Growth | - | -62.80% | -33.58% | -5.32% | 15.14% |
Net Cash Per Share | -4.30 | 38.29 | 103.89 | 165.46 | 184.99 |
Filing Date Shares Outstanding | 1.52 | 1.52 | 1.5 | 1.49 | 1.39 |
Total Common Shares Outstanding | 1.52 | 1.51 | 1.49 | 1.49 | 1.39 |
Working Capital | 39.86 | 90.57 | 145.45 | 155.67 | 176.58 |
Book Value Per Share | -3.01 | 37.72 | 106.25 | 153.15 | 179.74 |
Tangible Book Value | -4.59 | 57.09 | 158.78 | 227.52 | 249 |
Tangible Book Value Per Share | -3.01 | 37.72 | 106.25 | 153.15 | 179.74 |
Machinery | - | 0.84 | 0.57 | 0.57 | 1.17 |
Leasehold Improvements | - | 4.15 | 1.27 | 1.22 | 1.21 |